Overview

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Status:
Not yet recruiting
Trial end date:
2024-01-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of cenicriviroc mesylate (CVC) on arterial inflammation in people living with HIV.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Allergan, plc
Treatments:
Cenicriviroc
TAK-652